Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,061 to 1,080 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Patients Receiving cCTA and FFRCT >0.80 vs Patients Receiving cCTA and FFRCT≤0.80: serious adverse events | 12 of 4,737 43 of 4,737 | -0.7 points -1.0 to -0.4 | 9,474 | NCT02499679 Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care |
| Albiglutide vs Placebo: deaths from any cause | 196 of 4,731 205 of 4,732 | -0.2 points -1.0 to 0.6 | 9,463 | NCT02465515 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus |
| Albiglutide vs Placebo: Number of Participants With Non-fatal Serious Adverse Events (SAEs) | 891 of 4,717 974 of 4,715 | -1.8 points -3.4 to -0.2 | 9,432 | NCT02465515 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus |
| Albiglutide vs Placebo: Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Investigational Product (AELD) | 427 of 4,717 334 of 4,715 | 2.0 points 0.9 to 3.1 | 9,432 | NCT02465515 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus |
| Albiglutide vs Placebo: serious adverse events | 932 of 4,717 1,022 of 4,715 | -1.9 points -3.6 to -0.3 | 9,432 | NCT02465515 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus |
| Anesthesia Control Tower Monitoring vs Standard of Care Arm: Number of Participants With Postoperative Delirium | 1,502 of 4,681 1,506 of 4,711 | 0.1 points -1.8 to 2.0 | 9,392 | NCT03923699 Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety |
| Prioritized Clinical Decision Support vs Usual Care: deaths from any cause | 526 of 4,550 581 of 4,837 | -0.5 points -1.8 to 0.9 | 9,387 | NCT02451670 Reducing Cardiovascular Risk in Adults With Serious Mental Illness |
| Intensive Control of SBP vs Standard Control of SBP: Number of Participants With All-cause Mortality | 155 of 4,678 210 of 4,683 | -1.2 points -2.0 to -0.4 | 9,361 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Intensive Control of SBP vs Standard Control of SBP: Participants Who Developed End Stage Renal Disease | 12 of 4,678 8 of 4,683 | 0.1 points -0.1 to 0.3 | 9,361 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Intensive Control of SBP vs Standard Control of SBP: Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death | 243 of 4,678 319 of 4,683 | -1.6 points -2.6 to -0.7 | 9,361 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Intensive Control of SBP vs Standard Control of SBP: deaths from any cause | 155 of 4,678 210 of 4,683 | -1.2 points -2.0 to -0.4 | 9,361 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Intensive Control of SBP vs Standard Control of SBP: serious adverse events | 1,793 of 4,678 1,736 of 4,683 | 1.3 points -0.7 to 3.2 | 9,361 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Liraglutide vs Placebo: serious adverse events | 2,320 of 4,668 2,354 of 4,672 | -0.7 points -2.7 to 1.3 | 9,340 | NCT01179048 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results |
| Eptifibatide vs Placebo: serious adverse events | 66 of 4,686 60 of 4,643 | 0.1 points -0.4 to 0.6 | 9,329 | NCT00089895 EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) |
| Simvastatin Plus Ezetimibe vs Placebo: Non-hemorrhagic Stroke Among All of Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo | 131 of 4,650 174 of 4,620 | -0.9 points -1.7 to -0.2 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
| Simvastatin Plus Ezetimibe vs Placebo: Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo | 526 of 4,650 619 of 4,620 | -2.1 points -3.4 to -0.7 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
| Simvastatin Plus Ezetimibe vs Placebo: Coronary or Non-coronary Revascularization Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo | 284 of 4,650 352 of 4,620 | -1.5 points -2.5 to -0.5 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
| Simvastatin Plus Ezetimibe vs Placebo: Major Coronary Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo | 213 of 4,650 230 of 4,620 | -0.4 points -1.3 to 0.5 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
| Simvastatin Plus Ezetimibe vs Placebo: Major Vascular Events Analyzed Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo | 701 of 4,650 814 of 4,620 | -2.5 points -4.0 to -1.0 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
| Simvastatin Plus Ezetimibe vs Placebo: serious adverse events | 1,142 of 4,650 1,115 of 4,620 | 0.4 points -1.3 to 2.2 | 9,270 | NCT00125593 Study of Heart and Renal Protection |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=54
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02499679-sae",
"title": "Patients Receiving cCTA and FFRCT >0.80 vs Patients Receiving cCTA and FFRCT≤0.80: serious adverse events",
"summary": "12 of 4737 against 43 of 4737; risk difference -0.7 points, 95% interval -1.0 to -0.4; NCT02499679, Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care",
"record": "/library/comparisons/NCT02499679-sae",
"nct_id": "NCT02499679",
"kind": "serious-adverse-events",
"participants": 9474,
"risk_difference": {
"value": -0.006544226303567659,
"lower": -0.009853322436322238,
"upper": -0.0035434019558058557
},
"group_1": "12 of 4,737",
"group_2": "43 of 4,737",
"difference": "-0.7 points",
"interval": "-1.0 to -0.4",
"trial_title": "Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care"
},
{
"id": "NCT02465515-deaths",
"title": "Albiglutide vs Placebo: deaths from any cause",
"summary": "196 of 4731 against 205 of 4732; risk difference -0.2 points, 95% interval -1.0 to 0.6; NCT02465515, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",
"record": "/library/comparisons/NCT02465515-deaths",
"nct_id": "NCT02465515",
"kind": "deaths",
"participants": 9463,
"risk_difference": {
"value": -0.0018931891645417795,
"lower": -0.01004552452148738,
"upper": 0.0062503488918827284
},
"group_1": "196 of 4,731",
"group_2": "205 of 4,732",
"difference": "-0.2 points",
"interval": "-1.0 to 0.6",
"trial_title": "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=55",
"request_id": "KR5eDFQCjW983ErK"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant